Subject: PSID Up Nicely Today

SCV Client Spotlight
PSID Up Nicely Today
Hot Stock to WatchHot Stock to Watch

PositiveID Corporation (OTCBB: PSID)


Price: 0.0185

Change (%): + 0.003 (19.35)

Volume: 758,560
PSID Chart

PositiveID Corporation is an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing. Its wholly-owned subsidiary, Microfluidic Systems, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

Company Information Sheet

Pacific Therapeutics Ltd. (CNSX: PT)


Price: 0.05

Change (%): - 0.02 (28.57)

Volume: 9,500
PT Chart

Letter to Shareholders Regarding Positive Results from Recent Clinical Trial of PTL-202 for Fibrosis

Dear Shareholders

As announced on November 13, 2012 our phase 1 clinical trial that began in August 2012 wrapped up in September and had positive outcomes. Data from the trial showed a synergistic relationship resulting in an increase in the Active Ingredients in the blood and an increase in known therapeutic effects without any new side effects. These results may improve the competitiveness and commercial potential of PTL-202. PTL-202 is intended as a treatment for Pulmonary Fibrosis a 2 billion dollar market opportunity. This letter explains these results and their impact on your company with respect to the development of PTL-202, its competitiveness and commercial potential.

With the positive efficacy results from our pre-clinical testing of PTL-202 in animal models of fibrosis in hand your company initiated its first clinical trial of PTL-202 in August of this year. PTL-202 is a fixed dose combination of the approved drugs Pentoxifylline and NAC (the "Active Ingredients"). The development of PTL-202 is targeted at progressive scarring known as fibrosis including Idiopathic Pulmonary Fibrosis ("IPF") and Bronchiolitis Obliterans (excessive scarring) associated with lung transplant and Liver Cirrhosis. IPF is a disease that has no approved therapy in North America and is responsible for more deaths annually than either prostate or breast cancer. The one approved therapy in Europe sells for between 32,000 USD and 36,000 USD per patient per year!

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks